Cover Image

Explaining variability in early stages of [18F]‐flortaucipir tau‐PET binding: Focus on sex differences

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Dario Bachmann, Andreas Buchmann, Sandro Studer, Antje Saake, Katrin Rauen, Esmeralda Gruber, Roger M. Nitsch, Christoph Hock, Anton Gietl, Valerie Treyer
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hypertension and cerebral blood flow in the development of Alzheimer's disease
by: Dario Bachmann, et al.
Published: (2024)

Predicting cognitive decline with amyloid‐PET, plasma p‐tau217, Aβ42/40, and p‐tau217/Aβ42 in a community‐based cohort – relevance for clinical trial enrollment
by: Dario Bachmann, et al.
Published: (2025)

Survey among experts on the future role of tau‐PET in clinical practice and trials
by: Marie R. Vermeiren, et al.
Published: (2024)

Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET‐MR
by: Hossein Moein Taghavi, et al.
Published: (2024)

Resistance and resilience to tau pathology in Alzheimer's disease: Effects of age, sex, and APOE alleles
by: Yury Loika, et al.
Published: (2024)

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
by: Lara Blömeke, et al.
Published: (2024)

Plasma p‐tau217 and APOE genotype: Prodromal Alzheimer's disease staging
by: Ann M. Stowe, et al.
Published: (2026)

Comparison of three plasma p‐tau217 assays to detect PET‐confirmed Alzheimer's pathologies
by: Sayo Matsuura, et al.
Published: (2026)

Correction to “Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology”
Published: (2024)

Hallucinations and delusions are associated with elevated tau PET signal independent of age, clinical severity, and amyloid burden
by: Aubrey S Johnson, et al.
Published: (2026)

Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217
by: Qi Huang, et al.
Published: (2025)

Classifying mild cognitive impairment from normal cognition: fMRI complexity matches tau PET performance
by: Kay Jann, et al.
Published: (2025)

Protective Effects of Socioeconomic Status and Lifestyle on Amyloid‐ and White Matter Hyperintensity ‐Related Longitudinal Brain Atrophy and Cognitive Decline
by: Dario Bachmann, et al.
Published: (2025)

Diagnostic utility of plasma p‐tau217 differs by Alzheimer's disease tau‐based subtypes
by: Seyed Hani Hojjati, et al.
Published: (2025)

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia
by: Cassandra Marotta, et al.
Published: (2025)

Identifying cognitive test scores associated with early tau burden in Alzheimer's disease
by: Caitlin M. Terao, et al.
Published: (2025)

sTREM2 in discordant CSF Aβ42 and p‐tau181
by: Danni Li, et al.
Published: (2025)

Cross‐sectional study of plasma phosphorylated tau 217 in persons without dementia
by: Toni T. Saari, et al.
Published: (2025)

Biological sex and bilingualism: Its impact on risk and resilience for dementia
by: Noelia Calvo, et al.
Published: (2026)

Interchangeability of CSF and PET to identify Alzheimer's disease pathology
by: Samantha C. Burnham, et al.
Published: (2026)

Clinical and demographic factors modify the association between plasma phosphorylated tau‐181 and cognition
by: Corey J. Bolton, et al.
Published: (2024)

Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting
by: Rebecca Z. Rousset, et al.
Published: (2024)

Associations of plasma phosphorylated tau217 with cognitive impairment and brain microstructural alterations in Alzheimer's disease
by: Miguel Ángel Rivas‐Fernández, et al.
Published: (2026)

Plasma p‐tau217 for Alzheimer's disease diagnosis: a memory clinic implementation approach
by: Giorgia Brodini, et al.
Published: (2026)

Clinical validation of the Lilly SP‐X P‐tau217 assay: Performance in underrepresented cohorts
by: Michael E. Hodsdon, et al.
Published: (2025)

Social relationships, amyloid burden, and dementia: The ARIC‐PET study
by: Renée C. Groechel, et al.
Published: (2024)

Factors associated with discordant visual and quantitative amyloid PET results
by: Jasmin E Guevara, et al.
Published: (2026)

Disentangling the effects of sex and gender on APOE ɛ4–related neurocognitive impairment
by: Tatiana Dessy, et al.
Published: (2025)

Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease
by: Soheil Mohammadi, et al.
Published: (2025)

Association of item‐level responses to cognitive function index with tau pathology and hippocampal volume in the A4 Study
by: Idris Demirsoy, et al.
Published: (2025)

Investigating the amyloid–tau–neurodegeneration framework in Alzheimer's disease using semi‐supervised multimodal imaging data fusion
by: You Cheng, et al.
Published: (2026)

Body composition and plasma total‐tau, neurofilament light chain, and amyloid‐β: A population‐based study
by: Tosca O. E. de Crom, et al.
Published: (2024)

Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples
by: Anna E. Mammel, et al.
Published: (2025)

Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
by: Adam H. Dyer, et al.
Published: (2025)

Plasma p‐tau217 and cognitive impairment: Evaluating biomarker equity across racial/ethnic groups in HABS‐HD
by: Cellas A. Hayes, et al.
Published: (2026)

Inter‐scanner Aβ‐PET harmonization using barrel phantom spatial resolution matching
by: Gihan P. Ruwanpathirana, et al.
Published: (2024)

P‐tau217 testing impact on intended management of patients presenting with cognitive impairment: A randomized clinical utility study
by: Samantha C. Burnham, et al.
Published: (2025)

Cerebrospinal fluid sclerostin levels in the early Alzheimer's disease stages
by: Manuela Dicarlo, et al.
Published: (2026)

Evaluation of two clinical Centiloid analysis products for 18F‐florbetapir PET in cognitively unimpaired elders
by: Frank P. DiFilippo, et al.
Published: (2025)

Navigating late‐stage dementia: A perspective from the Alzheimer's Association
by: Kristen Clifford, et al.
Published: (2024)